Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 2, 2006, Pages 192-201

  Gardner, Erin R ^a   Burger, Herman ^a   van Schaik, Ron H ^a   van Oosterom, Allan T ^a   de Bruijn, Ernst A ^a   Guetens, Gunther ^a   Prenen, Hans ^a   de Jong, Floris A ^a   Baker, Sharyn D ^a   Bates, Susan E ^a   Figg, William D ^a   Verweij, Jaap ^a   Sparreboom, Alex ^a   Nooter, Kees ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; IMATINIB;

ADULT; AGED; ALLELE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TRANSPORT; EMBRYO; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HISTIOCYTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; STEADY STATE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; CELL LINE, TUMOR; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE FREQUENCY; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; STROMAL CELLS;

EID: 33746741049     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.05.003     Document Type: Article

References (38)

1. Judson I., Ma P., Peng B., Verweij J., Racine A., di Paola E.D., et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55 (2005) 379-386
2. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22 (2004) 935-942
3. Burger H., van Tol H., Boersma A.W., Brok M., Wiemer E.A., Stoter G., et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104 (2004) 2940-2942
4. Lepper E.R., Nooter K., Verweij J., Acharya M.R., Figg W.D., and Sparreboom A. Mechanisms of resistance to anticancer drugs. the role of polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6 (2005) 115-138
5. Imai Y., Nakane M., Kage K., Tsukahara S., Ishikawa E., Tsuruo T., et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1 (2002) 611-616
6. Hamada A., Miyano H., Watanabe H., and Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307 (2003) 824-828
7. Peng B., Lloyd P., and Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44 (2005) 879-894
8. Morisaki K., Robey R.W., Ozvegy-Laczka C., Honjo Y., Polgar O., Steadman K., et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56 (2005) 161-172
9. Sparreboom A., Loos W.J., Burger H., Sissung T.M., Verweij J., Figg W.D., et al. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 4 (2005) 650-653
10. Guetens G., De Boeck G., Highley M., Dumez H., Van Oosterom A.T., and de Bruijn E.A. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. J Chromatogr A 1020 (2003) 27-34
11. Hesselink D.A., van Schaik R.H., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245-254
12. van Schaik R.H., de Wildt S.N., van Iperen N.M., Uitterlinden A.G., van den Anker J.N., and Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 46 (2000) 1834-1836
13. Visser L.E., van Vliet M., van Schaik R.H., Kasbergen A.A., De Smet P.A., Vulto A.G., et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14 (2004) 27-33
14. van Schaik R.H. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 23 (2005) 513-522
15. National Center for Biotechnology Information Web site. Available from: URL:http://www.ncbi.nlm.nih.gov/RefSeq/. Accessed March 10, 2006.
16. Sham P.C., and Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59 (1995) 97-195
17. de Jong F.A., Marsh S., Mathijssen R.H., King C., Verweij J., Sparreboom A., et al. ABCG2 pharmacogenetics. ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10 (2004) 5889-5894
18. Sparreboom A., Gelderblom H., Marsh S., Ahluwalia R., Obach R., Principe P., et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76 (2004) 38-44
19. Zhou Q., Sparreboom A., Tan E.H., Cheung Y.B., Lee A., Poon D., et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 59 (2005) 415-424
20. Breedveld P., Pluim D., Cipriani G., Wielinga P., van Tellingen O., Schinkel A.H., et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec). implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65 (2005) 2577-2582
21. Houghton P.J., Germain G.S., Harwood F.C., Schuetz J.D., Stewart C.F., Buchdunger E., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64 (2004) 2333-2337
22. Burger H., and Nooter K. Pharmacokinetic resistance to imatinib mesylate. role of the ACB drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 3 (2004) 1502-1505
23. Burger H., van Tol H., Brok M., Wiemer E.A., de Bruijn E.A., Guetens G., et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4 (2005) 747-752
24. Marsh S., Kwok P., and McLeod H.L. SNP databases and pharmacogenetics. great start, but a long way to go. Hum Mutat 20 (2002) 174-179
25. Thomas J., Wang L., Clark R.E., and Pirmohamed M. Active transport of imatinib into and out of cells. implications for drug resistance. Blood 104 (2004) 3739-3745
26. Itoda M., Saito Y., Maekawa K., Hichiya H., Komamura K., Kamakura S., et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet 19 (2004) 308-312
27. Sakata T., Anzai N., Shin H.J., Noshiro R., Hirata T., Yokoyama H., et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 313 (2004) 789-793
28. Merino G., van Herwaarden A.E., Wagenaar E., Jonker J.W., and Schinkel A.H. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 67 (2005) 1765-1771
29. Peng B., Dutreix C., Mehring G., Hayes M.J., Ben-Am M., Seiberling M., et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44 (2004) 158-162
30. Rochat B. Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance. focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44 (2005) 349-366
31. Dutreix C., Peng B., Mehring G., Hayes M., Capdeville R., Pokorny R., et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54 (2004) 290-294
32. Bolton A.E., Peng B., Hubert M., Krebs-Brown A., Capdeville R., Keller U., et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53 (2004) 102-106
33. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., and Egorin M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76 (2004) 323-329
34. Baker S.D., van Schaik R.H., Rivory L.P., Ten Tije A.J., Dinh K., Graveland W.J., et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10 (2004) 8341-8350
35. Lepper E.R., Baker S.D., Permenter M., Ries N., van Schaik R.H., Schenk P.W., et al. Impact of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11 (2005) 7398-7404
36. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., and Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15 (2005) 693-704
37. O'Brien S.G., Meinhardt P., Bond E., Beck J., Peng B., Dutreix C., et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89 (2003) 1855-1859
38. Bernard S., Neville K.A., Nguyen A.T., and Flockhart D.A. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population. clinical implications. Oncologist 11 (2006) 126-135